Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients with Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

James F. Howard, Richard J. Nowak, Gil I. Wolfe, Miriam L. Freimer, Tuan H. Vu, John L. Hinton, Michael Benatar, Petra W. Duda, James E. MacDougall, Ramin Farzaneh-Far, Henry J. Kaminski, Richard Barohn, Mazen Dimachkie, Mamatha Pasnoor, Constantine Farmakidis, Tina Liu, Samantha Colgan, Michael G. Benatar, Tulio Bertorini, Rekha PillaiRobert Henegar, Mark Bromberg, Summer Gibson, Teresa Janecki, Bakri Elsheikh, Paige Matisak, Angela Genge, Amanda Guidon, William David, Ali A. Habib, Veena Mathew, Tahseen Mozaffar, William Hewitt, Deborah Barnett, Patricia Sullivan, Doreen Ho, Rebecca E. Traub, Manisha Chopra, Radwa Aly, Elham Bayat, Mohammad Abu-Rub, Shaida Khan, Dale Lange, Shara Holzberg, Bhupendra Khatri, Emily Lindman, Tayo Olapo, Lisa M. Sershon, Robert P. Lisak, Evanthia Bernitsas, Kelly Jia, Rabia Malik, Tiffany D. Lewis-Collins, Michael Nicolle, Aditi Sharma, Bhaskar Roy, Joan Nye, Michael Pulley, Alan Berger, Yasmeen Shabbir, Amit Sachdev, Kimberly Patterson, Zaeem Siddiqi, Mark Sivak, Joan Bratton, George Small, Anem Kohli, Mary Fetter, Lucy Lam, Brittany Harvey, Nicholas Silvestri, Kara Patrick, Karen Zakalik, Angela Pontius, Michelle Hoarty

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients with Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences